VivoSeq
Musculoskeletal

Arthritis

125

Pipeline Programs↗

41

Active Trials↗

54

Companies Involved↗

Arthritis is a highly competitive landscape with 125 programs across 54 companies. The most active players are Ampio Pharmaceuticals. Inc., Gilead, Cali Pharmaceuticals LLC. 30 therapies are approved with 35 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

34/100

Mech. Concentration

13/100

Completion Rate

77/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Ampio Pharmaceuticals. Inc.

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 1C

Cali Pharmaceuticals LLC

1 program

Phase 1GSK logo

GSK

2 programs

Phase 1S

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

Phase 2R

Rigel Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

123 of 144 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody1712%Protein / enzyme43%

Small molecule leads; the ring shows all 144 classified programs, each share of the total. Modality classified for 100% of 160 pipeline programs.

Analysis

Trial Status

193

clinical trials

Completed96 · 50%
Unknown status26 · 13%
Recruiting22 · 11%
Terminated20 · 10%
Not yet recruiting10 · 5%
Withdrawn9 · 5%
Other10 · 5%

Clinical Trials

Trial Activity

193 trials

A Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06860750·380 enrolled
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
Recruiting·—·Phase 1·NCT06222034·10 enrolled
A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo
Recruiting·Tasly Pharmaceutical Group Co., Ltd logoTasly Pharmaceutical Group Co., Ltd·Phase 3·NCT06000956·408 enrolled
Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission
Recruiting·TThe First Affiliated Hospital of Xiamen University·N/A·NCT03425812·140 enrolled
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis
Recruiting·MMayo Clinic·Phase 3·NCT05992883·240 enrolled
Knee Injections for Obese Patients With Knee Arthritis
Recruiting·MMayo Clinic·Phase 4·NCT06782529·40 enrolled
ToFAcitinib in Early Active Axial SpondyloarThritis:
Recruiting·—·Phase 4·NCT06112665·104 enrolled
Faecal Analyses in Spondyloarthritis Therapy
Recruiting·—·N/A·NCT03839862·50 enrolled
Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis
Recruiting·RRhode Island Hospital·Phase 3·NCT05990881·50 enrolled
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
Recruiting·AbbVie logoAbbVie·N/A·NCT05094128·352 enrolled
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT06222671·180 enrolled
Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis
Recruiting·LLaboratorios Silanes S.A. de C.V.·Phase 3·NCT06863701·72 enrolled
STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS
Recruiting·—·Phase 3·NCT03728478·260 enrolled
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
Recruiting·—·Phase 2·NCT06037811·30 enrolled
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
Recruiting·NNanfang Hospital, Southern Medical University·Phase 4·NCT06707194·340 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)